https://www.selleckchem.com/products/AT7519.html
21), higher total costs (adjusted incremental costs $9745), and an incremental cost-effectiveness ratio of $46,506 per quality-adjusted life-year gained.Results from the sensitivity analyses indicated the findings of the base-case analysis were robust. Contrary to previously published studies, our study established head-to-head comparisons of effectiveness and treatment-related costs of first-line EGFR-TKIs. Our findings suggest afatinib was the most cost-effective option among the three EGFR-TKIs. Contrary to previously published studie
Like
Comment
Share
